Wire · opportunities
Nurix Receives $10M Payment as Sanofi Initiates Phase 1 Trial of STAT6 Degrader SAR448272
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 August 2026 · Fusion42 review
Nurix received a $10 million milestone payment as Sanofi initiated a Phase 1 trial for SAR448272, an oral STAT6 degrader targeting type 2 inflammatory diseases. The trial's progress and subsequent data will influence Nurix's decision on co-development and co-promotion options in the US.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now have fresh proof that oral protein degraders can challenge injectable biologics in immune diseases. Watch the Phase 1 data closely to decide if you should join Nurix in betting on this oral degrader approach for better treatment access and convenience.
◆ Coverage
1 source · 5 Aug 2026
◆ Related on Wire
◆ Topics